Potential buyers prepared to chase arimoclomol approval, Orphazyme deputy chair says
The dream to see arimoclomol approved as a Niemann-Pick type C treatment will not die with Orphazyme, should the firm be dissolved through a takeover, Deputy Chair Bo Jesper Hansen tells MedWatch.
.jpg)
by christopher due karlsson, translated by daniel pedersen
Embattled biotech firm Orphazyme announced last week that several potential buyers had made bids to buy all of the company’s assets and operations.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
.jpg)
Orphazyme creditors approve restructuring plan
For subscribers
.jpg&w=384&q=75)
